Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective.

Purmonen, Timo; Puolakka, Kari; Bhattacharyya, Devarshi; Jain, Minal; Martikainen, Janne

Purmonen, Timo; Puolakka, Kari; Bhattacharyya, Devarshi; Jain, Minal; Martikainen, Janne.

Afiliação

Purmonen T; Novartis Finland Oy, Espoo, Finland.
Puolakka K; 2South Karelia Social and Health Care District, Lappeenranta, Finland.
Bhattacharyya D; 3Novartis Product Life Cycle Services-NBS, Novartis Healthcare Private Limited, Hyderabad, India.
Jain M; 3Novartis Product Life Cycle Services-NBS, Novartis Healthcare Private Limited, Hyderabad, India.
Martikainen J; 4School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Cost Eff Resour Alloc ; 16: 56, 2018.

Article em En | MEDLINE | ID: mdl-30479574

Palavras-chave

Biologics; Cost-effectiveness; Incremental cost effectiveness ratio; Psoriatic arthritis; Quality adjusted life years; Secukinumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google